Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Donor Hematopoietic Stem Cell Transplantation
NCT02660281Phase 1Completed
- Sponsor
- University of Rochester
- Start
- Oct 2015
- Primary completion
- Oct 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of haploidentical hematopoietic stem cells in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 14 more (5 arms), sponsored by University of Rochester. Primary endpoints: Time to Neutrophil and Platelet Engraftment at 42 days and Rate of Non-Engraftment and Secondary Graft Failure up to 120 months. Started Oct 2015; status: completed.
02
Drugs
haploidentical hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)lymphoma
Beyond the preview
Go deeper on NCT02660281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660281.